Form 4: Alnylam Pharmaceuticals Director Charles Elliott Sigal Reports Stock and Option Award

Director Charles Elliott Sigal reports acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Summary

• Charles Elliott Sigal, a director of Alnylam Pharmaceuticals, reported acquiring 775 shares of common stock represented by restricted stock units (RSUs) and 1,558 stock options on May 8, 2025.
• The RSUs were granted under the Amended and Restated 2018 Stock Incentive Plan and vest in full upon the earlier of the first anniversary of the grant date or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• The stock options have an exercise price of $258.35 and also vest in full upon the earlier of the first anniversary of the grant date or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• Following the reported transactions, Mr. Sigal directly owns 775 shares of common stock and 1,558 stock options, and indirectly owns 2,000 shares through Sigal Family Investments, LLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option awards to a director, which is a common practice.

Positives

• The acquisition of RSUs and stock options suggests confidence in the company's future performance from a board member.

Future Outlook

The vesting schedule of the RSUs and stock options incentivizes continued service and alignment with the company's long-term success.

Industry Context

Stock and option awards are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of RSUs and stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Alnylam Pharmaceuticals, Director, Charles Elliott Sigal, RSU, Stock Options, Beneficial Ownership, Form 4